AccuKit LCRT13: A set of 13 Biomarkers predictive for Lung Cancer in high risk patients based on age and smoking history
-
- Body Text: Lung cancer remains the most prevalent cause of cancer death in the United States (160,000 deaths each year). A recent NIH-sponsored study determined that annual screening by chest CT scan reduces mortality from lung cancer by more than 20%. However, the annual cost of CT scan screening all 7 million individuals at risk for lung cancer due to age and smoking history exceeds $5 billion. The AccuGenomics Lung Cancer Risk Test promises to identify the individuals genetically pre-disposed to lung cancer so that they can be prioritized for screening. This will markedly reduced cost of CT screening.
- Format: NGS Panel (Bronchoscopy Samples)
- Status: Recruited 360/800 patients
- Seeking Co-Development and Validation Partner
- Publication
AccuKit LCDT 4 Gene: A 4 biomarker test
- Have an idea for a co-development project using SNAQ-SEQ spike in controls? Contact us below with your idea and we’ll be happy to have our scientific staff discuss the opportunity.
- Current areas of interest include:
- Developing Minimum Residual Disease NGS and multiplex dPCR assays
- Extraction and processing spike-in controls
- RNA Controls for Whole Transcriptome Biomarker Validation Studies
- Digital PCR Multiplex controls
- Spike-In controls for Antibiotic and anti-viral resistance
- Current areas of interest include: